Cargando…

Impact of autoimmune diseases on outcome of patients with early breast cancer

Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criscitiello, Carmen, Bagnardi, Vincenzo, Esposito, Angela, Gelao, Lucia, Santillo, Barbara, Viale, Giulia, Rotmensz, Nicole, Goldhirsch, Aron, Curigliano, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239468/ https://www.ncbi.nlm.nih.gov/pubmed/27323400 http://dx.doi.org/10.18632/oncotarget.9966

Ejemplares similares

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
por: Gelao, Lucia, et al.
Publicado: (2014)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Best management of locally advanced inoperable breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Immune approaches to the treatment of breast cancer, around the corner?
por: Criscitiello, Carmen, et al.
Publicado: (2014)

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives
por: Criscitiello, Carmen, et al.
Publicado: (2014)

Tumour dormancy and clinical implications in breast cancer
por: Gelao, L, et al.
Publicado: (2013)

Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
por: Esposito, Angela, et al.
Publicado: (2015)

Toward precision medicine in inflammatory breast cancer
por: Viale, Giulia, et al.
Publicado: (2019)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
por: Montagna, E, et al.
Publicado: (2008)

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
por: Conforti, Fabio, et al.
Publicado: (2019)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
por: Munzone, Elisabetta, et al.
Publicado: (2006)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

International Web-based consultation on priorities for translational breast cancer research
por: Dowsett, Mitch, et al.
Publicado: (2007)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Immunity and autoimmunity in breast cancer
por: Curigliano, G
Publicado: (2011)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
por: Licata, Luca, et al.
Publicado: (2023)

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations()
por: Conforti, Fabio, et al.
Publicado: (2021)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Clinical trial update: International Breast Cancer Study Group
por: Price, Karen N, et al.
Publicado: (2005)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”?
por: Cardoso, Fatima, et al.
Publicado: (2018)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
por: Conforti, Fabio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_51da1vhsdr6pa5q4uohgvd23ef